Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2025 Jul 8;7(7):CD016098.
doi: 10.1002/14651858.CD016098.

Complement inhibitors for myasthenia gravis in adults

Laura M White  1   2 , Fiona J Clay  3 , Anne-Marie Forbes  4 , Ryan Yann Shern Keh  5 , James B Lilleker  5   6 , Jennifer Spillane  7 , Karen Storms  8 , Jon Sussman  5   6 , Katherine C Dodd  5   6
Affiliations

Complement inhibitors for myasthenia gravis in adults

Laura M White et al. Cochrane Database Syst Rev. .

Abstract

This is a protocol for a Cochrane Review (intervention). The objectives are as follows: To evaluate the benefits and harms of complement inhibitors for treating myasthenia gravis in adults compared with control treatment (placebo or standard care).

PubMed Disclaimer

Conflict of interest statement

LMW: I do not have any interests to disclose at this time.

FJC: I do not have any interests to disclose at this time.

A‐MF: I do not have any interests to disclose at this time.

RYSK: received a travel and accommodation grant from CSL Behring for the Peripheral Nerve Society meeting, Baltimore, July 2018.

JBL: declares personal payments from Biogen (webinar host November 2021, booked but not attended), Sanofi (Travel and speakers fees for STEPS forwards meeting 2022; consultancy in collaboration with VOLV 2021; and speaker fees February 2020), Hoffman‐La Roche (Participation in SMA HCRU Delphi Panel 2024; advisory meeting 2023, advisory board 2022), and Roche (advisory board 2020; writing support for a business case), neuromuscular study group (executive committee member (no fiduciary interest)), Myositis UK (attendance at global conference on myositis), British Myology Society (Vice chair (no fiduciary interest)), British Medical Association (production and update of an article for BMJ Best Practice).

JSp: declares speaker's fees and advisory board membership for Argenx, UCB, Johnson and Johnson, and Immunovant, as well as travel support from UCB, Johnson and Johnson, and Argenx. She is a PI for the ALXN1720 study.

KS: I do not have any interests to disclose at this time.

JSu: I do not have any interests to disclose at this time.

KCD: I do not have any interests to disclose at this time.

References

    1. Dresser L, Wlodarski R, Rezania K, Soliven B. Myasthenia gravis: epidemiology, pathophysiology and clinical manifestations. Journal of Clinical Medicine 2021;10(11):2235. - PMC - PubMed
    1. Sciancalepore F, Lombardi N, Valdiserra G, Bonaso M, Cappello E, Hyeraci G, et al. Prevalence, incidence, and mortality of myasthenia gravis and myasthenic syndromes: a systematic review. Neuroepidemiology 2024;9:1-24. - PubMed
    1. Binks S, Vincent A, Palace J. Myasthenia gravis: a clinical-immunological update. Journal of Neurology 2016;263(4):826-34. - PMC - PubMed
    1. Vincent A. Unravelling the pathogenesis of myasthenia gravis. Nature Reviews Immunology 2002;2(10):797-804. - PubMed
    1. Gilhus NE, Verschuuren JJ. Myasthenia gravis: subgroup classification and therapeutic strategies. Lancet Neurology 2015;14(10):1023-36. - PubMed

MeSH terms

Substances

LinkOut - more resources